SCHEMBL6285018

SCHEMBL6285018

CC(=NNC(=N)N)c1cn(S(=O)(=O)c2ccc3ccccc3c2)c2cc(F)ccc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 9/20 0.38
TNFSF11 O14788 2/20 0.37
F2 P00734 2/20 0.36
PRSS1 P07477 2/20 0.36
PRSS2 P07478 2/20 0.36
PRSS3 P35030 2/20 0.36
TNF P01375 2/20 0.36
LMNA P02545 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
TSHR P16473 2/20 0.35
ALDH1A1 P00352 2/20 0.35
GAA P10253 2/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
ALOX12 P18054 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
NPC1 O15118 1/20 0.35
USP2 O75604 1/20 0.35
DRD2 P14416 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6285015 1.00 HTR6 (0.38) HTR6TNFSF11F2PRSS1PRSS2
SCHEMBL6285292 0.90 TNFSF11 (0.46) HTR6TNFSF11F2PRSS1PRSS2
SCHEMBL6284290 0.90 LMNA (0.46) HTR6TNFSF11TNFLMNASMN1; SMN2
SCHEMBL6285290 0.90 TNFSF11 (0.46) HTR6TNFSF11F2PRSS1PRSS2
SCHEMBL6284291 0.90 LMNA (0.46) HTR6TNFSF11TNFLMNASMN1; SMN2
SCHEMBL6277945 0.87 CNR1 (0.39) HTR6TNFSF11F2PRSS1PRSS2
SCHEMBL6277944 0.87 CNR1 (0.39) HTR6TNFSF11F2PRSS1PRSS2
SCHEMBL6285168 0.86 HTR6 (0.42) HTR6MEN1KMT2A
SCHEMBL6285167 0.86 HTR6 (0.42) HTR6MEN1KMT2A
SCHEMBL6281927 0.86 EIF2AK3 (0.36) HTR6TNFSF11F2PRSS1PRSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US claimed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US claimed
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US disclosed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR2A HTR6 1/4885TNFSF11 1597/4885F2 4141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.